Aligos Therapeutics (ALGS)
(Real Time Quote from BATS)
$11.40 USD
-2.76 (-19.49%)
Updated Sep 19, 2024 10:00 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ALGS 11.40 -2.76(-19.49%)
Will ALGS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALGS
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Aligos Therapeutics (ALGS) a New Buy Stock
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
Other News for ALGS
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
Aligos posts initial mid-stage trial results for MASH candidate
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
Closing Bell Movers: Steelcase down 10% on soft top-line results, guidance
Aligos Therapeutics to announce Phase 2a topline results for ALG-055009 in MASH